Management of Familial Hypercholesterolemia in Pediatric Patients

Diagnosis and Risk Assessment

• The American Academy of Pediatrics recommends that children with a family history of premature cardiovascular disease undergo fasting lipid analysis and intensive intervention 1, 4, 5, 6
• Markedly elevated lipoprotein(a) (>75 nmol/L) is an independent risk factor for coronary heart disease, and when combined with elevated LDL-C, increases MI risk 10-fold or higher 2
• Familial clustering of similar lipid abnormalities suggests an inherited lipid disorder, likely heterozygous familial hypercholesterolemia 7, 8

Treatment Goals and Pharmacologic Therapy

• The American Academy of Pediatrics recommends reducing LDL-C by approximately 50% from baseline, with a primary target of LDL-C <100 mg/dL given family history of premature ASCVD 1, 3, 6, 7
• Statin therapy should be considered if LDL-C remains ≥160 mg/dL after lifestyle modification, or potentially even at current levels given extreme Lp(a) elevation and family history 1, 2, 6, 7
• Atorvastatin 10 mg once daily is a recommended first-line therapy for pediatric patients ≥10 years with HeFH 1, 3

Monitoring and Follow-Up

• Regular monitoring of lipid panels, liver enzymes, growth parameters, and adherence assessment is crucial while on statin therapy 1, 3
• The American Academy of Pediatrics recommends assessing height, weight, and sexual maturation in pediatric patients on statin therapy 1

Additional Risk Factor Management

• Blood pressure monitoring and management, tobacco avoidance, diabetes screening, and cardiovascular imaging are important aspects of comprehensive care 1, 3